Reference
Visentin A, et al. Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. Hematological Oncology 36: 366-369, No. 1, Feb 2018. Available from: URL: http://doi.org/10.1002/hon.2480 -Italy
Rights and permissions
About this article
Cite this article
Idelalisib. Reactions Weekly 1693, 248 (2018). https://doi.org/10.1007/s40278-018-43138-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-43138-2